Tiffany May, 59, was hiking alone in the Adelaide Hills last year when she fell and lost consciousness. When she came to, she was in intense pain and suspected she'd broken her hip. Hospital scans ...

Use of Amgen’s osteoporosis drug Prolia by those with advanced chronic kidney disease (CKD) can increase the risk of calcium loss in the blood, according to the FDA. The U.S. regulator has added a new ...

Prolia is a monoclonal antibody that binds to a specific protein on osteoclasts and decreases their activity. Osteoclasts are responsible for dissolving and breaking down old or damaged bone cells. By ...

Jan 19 (Reuters) - The U.S. Food and Drug Administration added a serious warning on the prescribing information for Amgen's (AMGN.O), opens new tab drug Prolia to treat bone loss as it increases the ...

Findings showed treatment with Prolia significantly increased the risk of developing severe hypocalcemia compared with bisphosphonates, especially in patients with advanced CKD. In patients with ...

Vancouver, British Columbia — A highly controlled retrospective analysis suggests that denosumab (Prolia) leads to greater reduction in fracture risk than does zoledronic acid (Reclast) among ...

The FDA approved Stoboclo and Osenvelt, denosumab biosimilars that could offer more affordable treatment options for osteoporosis and bone loss in various patient populations. Stoboclo and Osenvelt ...

Bosaya and Aukelso are FDA-approved biosimilars for managing bone health in cancer patients, offering cost-effective alternatives to Prolia and Xgeva. Bosaya targets bone loss prevention in prostate ...